In a planned, but not yet underway, clinical trial (NCT05574608), 12 patients with relapsed/refractory AML will receive fludarabine and cyclophosphamide chemotherapy followed by infusion of CD123-CAR-NK cells. The gene discussed is IL3RA; the disease is acute myeloid leukemia.